Monthly Archives:

Early Identification of Metastatic Disease in Prostate Cancer: RADAR Group Recommendations

An Interview with E. David Crawford, MD, and Daniel P. Petrylak Please expand on the current lack of consensus regarding eligibility criteria, type of imaging modality, and frequency of scanning, particularly for M0 CRPC patients. Dr. Crawford: The transition to metastatic disease in men with prostate cancer is a seminal event in the management of these patients. Recent data suggest ... Read More »

Antigen Spreading and Immune-Based Therapies: An Interview with the National Cancer Institute’s James L. Gulley

Let’s start with the basic question: how are immunotherapies different from other classes of anti-cancer agents? James L. Gulley, MD, PhD: To understand why immunotherapeutic agents might produce different outcomes than those expected for other modalities, we need to first lay a foundation for understanding how exactly these agents are different. It’s important to note that therapeutic vaccines, unlike conventional ... Read More »

The Changing Landscape of Prostate Cancer

Prostate cancer is the most common non-cutaneous malignancy in men, accounting for more than 28,000 deaths in the United States every year; however, how to prevent, diagnosis, and treat prostate cancer remains one of the most debatable topics in oncology today. Read More »

Molecular Pathogenesis and Progression of Prostate Cancer

Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous malignancy and second leading cause of cancer-related deaths in US males. Clinically, locally confined disease is treated surgically and/or with radiation therapy. Read More »

Molecular Diagnosis of Prostate Cancer: Are We Up to Age?

Prostate cancer (PCa), a highly heterogeneous disease, is the one of the leading cause of morbidity and mortality in the developed countries. Historically used biomarkers such as prostatic acid phosphatase (PAP), serum prostate-specific antigen (PSA), and its precursor have not stood the challenge of sensitivity and specificity. Read More »

MCRPC Featured Article 1

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials   Read More »

Introduction to the IMPACT Trial

Lower Baseline prostate-specific antigen is associated with a greater overall survival benefit from Sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (Impact Trial)   Read More »